Vertex reported a positive Phase 3 Rainier readout for povetacicept, a dual BAFF/APRIL inhibitor, and is moving to file a Biologics License Application with the U.S. Food and Drug Administration. The company says the trial achieved a roughly 52% reduction in urine protein-to-creatinine ratio (UPCR) at the interim timepoint, a magnitude analysts called the highest placebo-adjusted proteinuria response seen in Phase 3 IgAN studies. Vertex acquired the asset via its $4.9 billion purchase of Alpine Immune Sciences and signaled plans for an accelerated review pathway. The development places Vertex directly into an active commercial race with Otsuka (Voyxact) and Vera Therapeutics (atacicept), and investors have reacted positively to the data. Vertex and analysts cited Rainier’s numerical superiority on proteinuria as the clinical differentiator; the company said it expects to complete and submit a BLA by the end of March. Regulatory filings and potential accelerated approval would hinge on short-term proteinuria reduction as a surrogate endpoint for progression in immunoglobulin A nephropathy (IgAN), a rare kidney disease with a high risk of end-stage renal failure. Named sources: Vertex Pharmaceuticals (company statements), Rainier Phase 3 trial data, industry analysts. For context, UPCR reduction is a commonly used surrogate marker in nephrology trials to evaluate effects on kidney disease activity; regulators may grant accelerated approval based on robust proteinuria responses when supported by safety and durability data.